JP2014111672A5 - - Google Patents

Download PDF

Info

Publication number
JP2014111672A5
JP2014111672A5 JP2014056829A JP2014056829A JP2014111672A5 JP 2014111672 A5 JP2014111672 A5 JP 2014111672A5 JP 2014056829 A JP2014056829 A JP 2014056829A JP 2014056829 A JP2014056829 A JP 2014056829A JP 2014111672 A5 JP2014111672 A5 JP 2014111672A5
Authority
JP
Japan
Prior art keywords
derivatives
pharmaceutical composition
alcohol
pyrrolidone
poe
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014056829A
Other languages
English (en)
Japanese (ja)
Other versions
JP6215102B2 (ja
JP2014111672A (ja
Filing date
Publication date
Application filed filed Critical
Priority to JP2014056829A priority Critical patent/JP6215102B2/ja
Priority claimed from JP2014056829A external-priority patent/JP6215102B2/ja
Publication of JP2014111672A publication Critical patent/JP2014111672A/ja
Publication of JP2014111672A5 publication Critical patent/JP2014111672A5/ja
Application granted granted Critical
Publication of JP6215102B2 publication Critical patent/JP6215102B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014056829A 2012-09-14 2014-03-19 医薬組成物 Expired - Fee Related JP6215102B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2014056829A JP6215102B2 (ja) 2012-09-14 2014-03-19 医薬組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2012203293 2012-09-14
JP2012203293 2012-09-14
JP2014056829A JP6215102B2 (ja) 2012-09-14 2014-03-19 医薬組成物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2013176862A Division JP5686874B2 (ja) 2012-09-14 2013-08-28 医薬組成物

Publications (3)

Publication Number Publication Date
JP2014111672A JP2014111672A (ja) 2014-06-19
JP2014111672A5 true JP2014111672A5 (enExample) 2016-09-23
JP6215102B2 JP6215102B2 (ja) 2017-10-18

Family

ID=49226452

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013176862A Expired - Fee Related JP5686874B2 (ja) 2012-09-14 2013-08-28 医薬組成物
JP2014056829A Expired - Fee Related JP6215102B2 (ja) 2012-09-14 2014-03-19 医薬組成物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2013176862A Expired - Fee Related JP5686874B2 (ja) 2012-09-14 2013-08-28 医薬組成物

Country Status (7)

Country Link
US (1) US20150238606A1 (enExample)
EP (1) EP2895164A1 (enExample)
JP (2) JP5686874B2 (enExample)
CN (1) CN104619320A (enExample)
IN (1) IN2015DN02377A (enExample)
RU (1) RU2621615C2 (enExample)
WO (1) WO2014042043A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010117089A2 (en) 2009-04-09 2010-10-14 Pola Pharma Inc. Antimycotic pharmaceutical composition
KR101409792B1 (ko) 2009-04-09 2014-06-19 니혼노야쿠가부시키가이샤 항진균성 약제학적 조성물
US8952044B2 (en) 2009-08-25 2015-02-10 Pola Pharma Inc. Antimycotic pharmaceutical composition
EP2579847A1 (en) 2010-06-11 2013-04-17 Pola Pharma Inc. Antimycotic pharmaceutical composition
JP6265624B2 (ja) * 2012-05-11 2018-01-24 ロート製薬株式会社 ルリコナゾール含有外用医薬組成物
CN104619703A (zh) 2012-09-14 2015-05-13 宝丽制药股份有限公司 具有结晶习性的晶体以及通过对所述晶体进行加工获得的药物组合物
JP5460797B1 (ja) * 2012-09-14 2014-04-02 株式会社ポーラファルマ アミド誘導体及び安定性指標としてのその使用
EP2895165B1 (en) 2012-09-14 2016-12-14 Pola Pharma Inc. Crystal and pharmaceutical preparation containing the same crystal
CN104619704B (zh) 2012-09-14 2017-12-05 宝丽制药股份有限公司 表面自由能用于分化评价晶体的用途，基于表面自由能作为指标评价的晶体，以及通过包含所述晶体制备的药物组合物
JP5589110B1 (ja) 2013-03-08 2014-09-10 株式会社ポーラファルマ 晶癖を有する結晶及び該結晶を有効成分として含有する医薬組成物
JP6503627B2 (ja) * 2013-03-28 2019-04-24 大正製薬株式会社 医薬液体組成物
JP5680161B1 (ja) 2013-09-06 2015-03-04 株式会社ポーラファルマ 晶癖を有する結晶及び該結晶を有効成分として含有する医薬組成物
JP6242655B2 (ja) * 2013-10-29 2017-12-06 リンテック株式会社 機能性物質の放出方法、機能性物質の放出用キット及び放出性組成物
JP5587488B1 (ja) 2013-12-12 2014-09-10 株式会社ポーラファルマ ルリコナゾールを含有する製剤の評価方法及び指標物質
MX2018014485A (es) * 2016-05-25 2019-08-12 Glenmark Pharmaceuticals Ltd Composiciones topicas estables de luliconazol.
CN107865825B (zh) * 2016-09-28 2022-05-20 四川海思科制药有限公司 一种卢立康唑外用喷雾剂药物组合物及其制备方法
WO2018179170A1 (ja) * 2017-03-29 2018-10-04 日本農薬株式会社 感染症を治療するための医薬組成物
CA3081163A1 (en) * 2017-10-30 2019-05-09 Kaken Pharmaceutical Co., Ltd. External preparation for treating trichophytosis unguium
CN108143711A (zh) * 2018-01-13 2018-06-12 天津双硕医药科技有限公司 一种含有卢立康唑的外用乳膏组合物
US10898470B1 (en) * 2019-08-13 2021-01-26 Sato Pharmaceutical Co., Ltd. Pharmaceutical composition containing antifungal agent as active ingredient
CN113774390B (zh) * 2021-08-12 2023-08-04 上海新阳半导体材料股份有限公司 一种用于化学机械抛光后的清洗液及其制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2005959B1 (en) 2006-03-08 2015-01-21 Nihon Nohyaku Co., Ltd. Pharmaceutical composition for external use
NZ571818A (en) 2006-03-08 2011-10-28 Nihon Nohyaku Co Ltd External pharmaceutical composition comprising luliconazole and an alpha-hydroxycarboxylic acid such as lactic acid, glycolic acid or malic acid.
AU2006339842B2 (en) 2006-03-08 2012-06-07 Nihon Nohyaku Co., Ltd. Pharmaceutical composition for external use
HUE029707T2 (en) * 2007-08-27 2017-03-28 Nihon Nohyaku Co Ltd Anti-fungal dermatitis
US20100204293A1 (en) * 2007-09-05 2010-08-12 Pola Pharma Inc. Pharmaceutical composition
PL2191828T3 (pl) 2007-09-05 2017-02-28 Pola Pharma Inc. Przeciwgrzybicza kompozycja farmaceutyczna
CN101808638B (zh) 2007-09-05 2012-07-25 宝丽制药股份有限公司 抗真菌组合物
US20090130232A1 (en) * 2007-11-20 2009-05-21 Mohammed Zahra Composition and method for treatment of oral inflammation an ulceration
US8445717B2 (en) * 2008-11-20 2013-05-21 Chd Bioscience, Inc. α-Keto alkylperacids and methods for producing and using the same
JP5654497B2 (ja) * 2009-02-13 2015-01-14 トピカ ファーマシューティカルズ，インコーポレイテッド 抗真菌製剤
KR101409792B1 (ko) * 2009-04-09 2014-06-19 니혼노야쿠가부시키가이샤 항진균성 약제학적 조성물
WO2010117089A2 (en) * 2009-04-09 2010-10-14 Pola Pharma Inc. Antimycotic pharmaceutical composition
US8952044B2 (en) * 2009-08-25 2015-02-10 Pola Pharma Inc. Antimycotic pharmaceutical composition
EP2579847A1 (en) * 2010-06-11 2013-04-17 Pola Pharma Inc. Antimycotic pharmaceutical composition
AU2012219321C1 (en) * 2011-02-17 2016-02-04 Armis Biopharma, Inc. Compositions comprising peroxy alpha-ketocarboxylic acid and methods for producing and using the same

Similar Documents

Publication Publication Date Title
JP2014074012A5 (enExample)
RU2015108930A (ru) Фармацевтическая композиция, содержащая луликоназол
HRP20210183T1 (hr) 18f-obilježeni inhibitori specifičnog membranskog antigena prostate (psma) i njihova uporaba kao sredstava za vizualizaciju raka prostate
MX2015011074A (es) Composicion que comprende un compuesto lipido, un triglicerido y un tensioactivo, y metodos de uso de la misma.
JP2012523410A5 (enExample)
MX2017009489A (es) Composicion auto-emulsionante de acido graso ?3.
JP2018526325A5 (enExample)
JP2015078230A5 (enExample)
JP2014129360A5 (enExample)
JP2016511753A5 (enExample)
JP2020011967A5 (enExample)
RU2015146957A (ru) Производные доластатина 10 и ауристатинов
MY189770A (en) Biaryl derivative as gpr120 agonists
JP2014218522A5 (enExample)
SG10201809228RA (en) Lyophilized formulation of hgf
HK1219222A1 (zh) 包含降血脂药的制剂
RU2016137349A (ru) Успокоительный феромон для кошек
AR080127A1 (es) Inhibidores de la amida hidrolasa de acidos grasos, composiciones farmaceuticas y sus usos
JP2013223715A5 (enExample)
PE20160037A1 (es) Formulacion farmaceutica que comprende fosfatidilcolina para el tratamiento de colitus ulcerosa
BR112017017643A2 (pt) formulação farmacêutica tópica
JP2016079180A5 (enExample)
JP2014508170A5 (enExample)
JP6900189B2 (ja) 外用組成物
JP2018095567A5 (enExample)